| Assessment Status | Rapid Review Complete |
| HTA ID | 25047 |
| Drug | Lenacapavir |
| Brand | Sunlenca® |
| Indication | Lenacapavir (Sunlenca®) in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen. |
| Assessment Process | |
| Rapid review commissioned | 25/07/2025 |
| Rapid review completed | 08/08/2025 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that lenacapavir (Sunlenca®) not be considered for reimbursement at the submitted price. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here.